NICE Throws AZ's Lynparza A Bone
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, may decide after all to recommend AstraZeneca's PARP inhibitor Lynparza (olaparib) as a maintenance treatment for a subset of NHS patients with maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer. If it sees the right evidence, it says it may be able to use flexibilities to consider more expensive treatments.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.